Premium
Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome
Author(s) -
Schneider C.,
Gold R.,
Schäfers M.,
Toyka K.V.
Publication year - 2002
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.10026
Subject(s) - medicine , discontinuation , polymyositis , mycophenolate , refractory (planetary science) , mycophenolic acid , ulcerative colitis , methylprednisolone , ankylosing spondylitis , tacrolimus , gastroenterology , dermatology , surgery , transplantation , disease , physics , astrobiology
Mycophenolate mofetil 1.5 g daily (30 mg/kg body weight) was given to a patient with ankylosing spondylitis, ulcerative colitis, and severe refractory polymyositis after conventional treatment regimes had failed. No severe side effects occurred. Considerable improvement of clinical symptoms and electromyographic findings were seen within 6 months after the initiation of mycophenolate mofetil, allowing for tapering and discontinuation of methylprednisolone. Mycophenolate mofetil may be considered as an useful alternative in the treatment of polymyositis when standard therapeutic regimens fail. © 2002 John Wiley & Sons, Inc. Muscle Nerve 25: 286–288, 2002 DOI 10.1002/mus.10026